Regulating the advertising and promotion of stem cell therapies (Q50122051)

25 February 2018

title

Regulating the advertising and promotion of stem cell therapies (English)

1 reference

25 February 2018

author name string

Barbara von Tigerstrom

series ordinal

1 reference

25 February 2018

publication date

7 November 2017

1 reference

25 February 2018

published in

Regenerative Medicine

1 reference

25 February 2018

volume

1 reference

25 February 2018

issue

1 reference

25 February 2018

page(s)

815-826

1 reference

25 February 2018

Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy Perspective

cites work

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Medicine's Wild West--Unlicensed Stem-Cell Clinics in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Regulatory loophole enables unproven autologous cell therapies to thrive in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Australasian College of Sports Physicians-position statement: the place of mesenchymal stem/stromal cell therapies in sport and exercise medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Direct-to-consumer stem cell marketing and regulatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Professional regulation: a potentially valuable tool in responding to "stem cell tourism"

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Global Distribution of Businesses Marketing Stem Cell-Based Interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Representations of stem cell clinics on Twitter

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Risk disclosure and the recruitment of oocyte donors: are advertisers telling the full story?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

U.S. National Football League athletes seeking unproven stem cell treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Unproven stem cell-based interventions & physicians' professional obligations; a qualitative study with medical regulatory authorities in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Current practices and reform proposals for the regulation of advanced medicinal products in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

Myths, misconceptions and myopia: searching for clarity in the debate about the regulation of consumer genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FRME-2017-0057

21 January 2018

Identifiers

DOI

10.2217/RME-2017-0057

1 reference

25 February 2018

1 reference

25 February 2018